GlassScriptPhysician profile
Amir Sulman
NPI 1508481045
$1,288.32
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $370 · 2023: $386 · 2024: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $513.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $365.69 | 2021-2023 | Dupixent |
| Genzyme Corporation | $363.05 | 2021-2024 | |
| Novo Nordisk INC | $243.09 | 2022-2023 | Wegovy |
| Glaxosmithkline, LLC. | $121.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $115.07 | 2022 | |
| Amgen INC. | $25.46 | 2021 | |
| Aurinia Pharma U.S., INC. | $23.25 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.84 | 2023 | Takhzyro |
| Astrazeneca Pharmaceuticals LP | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Sulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.